OVAGEN 20MG

Ovagen 20mg is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Leu (EDL), developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. With a molecular formula of C₁₅H₂₅N₃O₈ and molecular weight of 375.37 g/mol, Ovagen is the dedicated dual-tissue member of the Khavinson bioregulator family — uniquely studied for regulatory activity across both hepatic tissue and gastrointestinal epithelium, making it one of the most versatile organ-targeting compounds in the Khavinson peptide system.

Research into Ovagen centers on its proposed epigenetic mechanism of chromatin decondensation in hepatocytes and GI epithelial cells, restoring gene expression programs for protein synthesis and cellular regeneration that decline with aging. Notably, published research reports an 18-fold increase in liver cell regeneration markers in Ovagen-exposed models, with more pronounced effects observed in aged cell populations — consistent with the broader Khavinson bioregulator hypothesis. Additional studies have examined Ovagen’s effects on liver fibrosis reduction, GI mucosal layer protection against antibiotic and chemotherapy damage, digestive enzyme modulation, and inhibition of HIV-1 protease activity through the EDL peptide sequence’s resolved enzyme-binding properties.

Beyond Health Lab supplies Ovagen 20mg as a research-grade lyophilized compound, HPLC-verified for 99% purity, shipped within 24 hours from Mexico.

For research use only. Not intended for human or animal consumption.

FAQ:

What is Ovagen and what tissues does it target?
Ovagen (Glu-Asp-Leu / EDL) is a Khavinson tripeptide bioregulator uniquely studied for regulatory activity across two organ systems simultaneously: hepatic tissue (hepatocytes and hepatic stellate cells) and gastrointestinal epithelium. This dual-tissue profile distinguishes it from Livagen (KEDA), which targets hepatic tissue specifically. Ovagen’s proposed epigenetic mechanism involves chromatin decondensation in both tissue compartments, restoring gene expression programs for cellular regeneration and protein synthesis that are progressively silenced during aging.

What are the most significant preclinical findings associated with Ovagen research?
Published research documents an 18-fold increase in liver cell regeneration markers in Ovagen-exposed models — with maximum effects in aged cell populations, consistent with the bioregulator hypothesis that EDL primarily restores age-depleted signaling. Additional studies have examined liver fibrosis reduction through inflammatory pathway modulation, GI mucosal protection against antibiotic and chemotherapy-induced damage, digestive enzyme activity normalization in rodent small intestine models, and HIV-1 protease inhibition through the EDL peptide sequence’s resolved enzyme-binding structure (RCSB Protein Data Bank). Key published references: Khavinson et al. Biochemistry (Moscow) 2000, Popovich et al. Bull Exp Biol Med 2003, Anisimov et al. Biogerontology 2010.

How does Ovagen compare to Livagen in the Khavinson hepatic research system?
Both Ovagen (EDL) and Livagen (KEDA) are Khavinson bioregulators studied for hepatic tissue regulatory effects, but with distinct profiles. Livagen’s published data is more concentrated on hepatic-specific chromatin remodeling, with an additional immune research profile covering lymphocyte modulation. Ovagen’s dual hepatic-GI profile and its HIV-1 protease enzyme-binding data make it a broader research tool for combined gut-liver axis aging studies, GI mucosal protection models, and anti-viral mechanism research.

How should Ovagen 20mg be stored?
Store lyophilized Ovagen at 2–8°C away from light and moisture. Once reconstituted with bacteriostatic water, keep refrigerated and use within 28 days for optimal stability and research-grade performance.